Introducing our team of healthcare business and investment professionals who have been drawn together from within Japan and overseas by MIJ’s investment philosophy:
Jun KATSURAPresident & CEO
Jun Katsura has previously served as Executive Director of Business Unit Head at AstraZeneca Japan and Merck Serono Japan. As a member of AstraZeneca Global’s Emerging Compound Development Decision-making Committee, he was involved in emerging compound-related evaluation and decision-making processes. Based on this experience, he evaluates the potential of new drug and medical device digital health enterprises and provides marketing strategy advice. Katsura is one of the very few Japanese people who have worked as a senior manager in the global headquarters of a foreign-owned pharmaceuticals company.
Through this experience, he possesses broad human networks in the healthcare field in not only Japan but also Europe, Israel, the United States, and China, as well as high-quality marketing capabilities.
Mitsuhiro HATADirector & Chief Administrative Officer
Mitsuhiro Hata is Visiting Professor, Hitotsubashi University Business School (HUB)/Lecturer, Waseda Business School (WBS) . He is a pioneer in the field of business development consulting for start-ups and large corporations. Beginning with healthcare, he has an impressive performance record as an advisor in the field of innovation overall in addition to an extensive network of supporters. Prior to MIJ’s establishment, he gained a wealth of experience and solid performance record in fund operation as the GP of the CareNet Innovation Investment Limited Partnership. After working at the Boston Consulting Group, Hata led management, operation, and business development at CareNet, Inc. in the company’s early days as one of its founders. At BD Sprint Partners, which he founded, he provides multifaceted support for leading large companies’ business development. Hata graduated from the Faculty of Commerce and Management, Hitotsubashi University.
Kenji HARADA, Ph.D.Director & Chief Venture Capitalist
He worked as a group leader of researching and developing medical drugs at a leading Japanese chemical company, he had committed pharmaceutical researches about 10 years. After moving to the head office, he was focusing on running due diligence on medical drug candidates and platform technologies coming from European and American biotech companies, from the aspect of science and intellectual properties. He started his carrier at JAFCO, a Japanese largest venture capital firm, for more than 16 years, he had been investing in Japanese and American biotechnologies and served on the board of several investees. He established rich network with most of major pharmaceutical companies and many of leading venture capitals. He is an immunologist by training, earned his PhD in pharmacology at the university of Tokyo.
Ko TAKAHASHIChief Strategist
Ko Takahashi has nearly 40 years’ experience on the frontlines and in management of the medical drug field. Working for an American drug manufacturer for some 20 years, he played leadership roles in various areas, from the frontlines of sales activities to marketing, new drug planning and development strategies, and business development. Sensing the inefficiency of drug company push marketing and foreseeing upcoming market changes towards anti-body drugs, regenerative medicine, gene therapy, and other specialty drugs, Takahashi joined CareNet, Inc.—a company providing lifelong learning for physicians—in 2006. Though his activities in CareNet’s business development and management, he has built up networks with healthcare enterprises with the United States, Europe, Israel, and India. He provides support for the marketing activities of many drug manufacturers based on a philosophy of “The success of pharmaceuticals and medical devices comes from development strategies premised on post-sales marketing”, and possesses extensive networks in these industries. The database construction using research and information-gathering from specialist physicians in various fields and medical workplaces, and the strategy-building based on this knowledge, that Takahashi provides are powerful weapons for start-up companies.
Shigeru Yasue previously worked with Mitsubishi UFJ Capital, Japanese largest financial group’s venture capital arm for more than twenty years, since 2000. He is a founding member of Mitsubishi UFJ Capital’s Life Science Department. His investment area covers not only Japanese biotechs but also US and European biotechs, together with project finance for the pharmaceutical company’s global clinical studies. He served on the board of several portfolio companies and achieved 12 exits including Nasdaq and Tokyo Stock Exchange IPOs, M&A and Success fee payments.
Tatsuo Tanaka has around 40 years of experience working for European and American pharmaceutical companies. During his time at Eli Lilly Japan K.K., he worked at the company’s head office in the United States for approx. two-and-a-half years as marketing manager for endocrine system drugs. After returning to Japan, he served as general director for marketing at Warner Lambert Inc., Janssen Pharmaceutical K.K. (then Janssen-Kyowa K.K.), and Nippon Boehringer Ingelheim Co., Ltd. TANAKA possesses a broad human network within the pharmaceuticals industry and among major medical supplies wholesalers.
After taking doctorial courses in bio-medical engineering, Yukinori Kanekawa taught at a vocational school for clinical engineering professionals, following which he worked at Japan’s Pharmaceuticals and Medical Devices Agency (PDMA) and Ministry of Health, Labour and Welfare, where his responsibilities included medical devices and pharmaceuticals administration. Utilizing his knowledge in the fields of engineering, basic medicine, and clinical healthcare, he was mainly responsible for work related to innovative medical devices applying advanced technologies. With medical finance tightening and society’s healthcare and medical needs changing, Kanekawa sensed limitations to healthcare under Japan’s current social security system. Resonating with MIJ’s mission to support start-ups generating new value in healthcare through the circulation of private capital, Kanekawa joined MIJ in September 2018. At MIJ he is responsible for seeds discovery, technology evaluation, and drug development strategies.
His qualifications include ME Technologist (Class 1) and a Master’s degree from the Graduate School of Engineering, Hokkaido University.
Masayuki KAWAHARAMember, Investment Committee
He has more than 10 years of experience in the medical device and drug development field, including four and a half years at a regulatory agency (PMDA).
He was engaged in medical affairs for the launch of existing and new drugs at a foreign-owned pharmaceutical company in Japan, and in the development of biopharmaceuticals at a U.S. subsidiary of a domestic pharmaceutical company.
He is the first MD with industry experience to join the Pharmaceuticals and Medical Devices Agency (PMDA), where he served as a medical reviewer in the field of medical devices and pharmaceuticals, and after leaving PMDA, he has been engaged in clinical development consulting in addition to running a medical practice and visiting nursing business.
He has extensive clinical experience in aesthetic dermatology, cosmetic surgery, obstetrics and gynecology, internal medicine, pediatrics, neurosurgery, and anesthesiology, as well as knowledge of both industry and regulatory agencies, pharmaceuticals and medical devices.
Tamio TERAMOTO, M.D.
After graduating from the Faculty of Medicine, The University of Tokyo, he joined The University of Tokyo Hospital (Department of Internal Medicine No. 1), and he has also had the experience of studying at the University of Chicago in the United States. After joining Teikyo University, he served as vice-president of the Teikyo University Hospital and as Dean of the School of Medicine before taking up his current position as director of the Teikyo Academic Research Center (TARC). Teramoto is a leading researcher in the fields of endocrinology, metabology, and arteriosclerosis science, and has served as president of the Japanese Society of Internal Medicine and Japan Atherosclerosis Society. He is currently a director of the Japanese Association of Medical Sciences and a director of the Japanese Medical Specialty Board. He has also served on the Pharmaceutical Affairs and Food Sanitation Council (Ministry of Health, Labour and Welfare) and numerous other committees.
Kensei YAMAGUCHI, M.D.
Graduating from the National Defense Medical College in March 1990, Yamaguchi joined the Second Internal Medicine Department of the National Defense Medical College Hospital in April of the same year. After working at the Self-defense Forces Central Hospital, he joined the Saitama Cancer Center in August 1996, serving as Head Physician of the Clinical Laboratory Department, Head Physician of the Gastroenterology Department, and then Chief/Director of the Gastroenterology Department. In October 2015, Yamaguchi was appointed as Director of the Gastroenterological Chemotherapy Department, Gastroenterology Center, at The Cancer Institute Hospital of JFCR. Since then, he has also jointly served as Director of the Clinical Trial Standardization Department, Clinical Trial Development Center; Vice Director of the Clinical Trial Support Department, Clinical Trial Development Center; and Junior Hospital Director. In July 2018, Yamaguchi was appointed as Director of the Clinical Trial Development Center.
He is a member of the Gastric Cancer Treatment Guidelines Committee member; Board Certified Fellow of the Japan Gastroenterological Endoscopy Society; Provisional Trainer of the Japanese Society of Medical Oncology; member of the Board of Councilors of the Japanese Society of Medical Oncology; and part-time instructor (chemotherapy advisor) at the Digestive Tract/General Surgery Department, Saitama Medical Center.
Toru SUZUKI, M.D.
Toru Suzuki is Professor/Chair of Cardiovascular Medicine at the University of Leicester, United Kingdom. He joined the University of Leicester in 2014 from the University of Tokyo.
As a clinical academic, he is a qualified medical practitioner in the UK with specialist registration in cardiology, and practices at the Glenfield Hospital of the University of Leicester Hospitals NHS Trust. Glenfield Hospital is one of the UK’s and Europe’s main cardiac specialist hospitals where he practices as a consultant cardiologist. From 2020, he has been appointed Associate Dean of the College of Life Sciences and inaugural Director of the Leicester Life Sciences Accelerator and is developing an ecosystem for innovation in clinical/healthcare, with a focus on clinical data and partnerships.
Tel Aviv Office
Roy’s career-long advisory record combines finance, strategic development and management success with an innovation perspective and a profound knowledge of Japan-Israel business relations. In his Investment Banking career at GCA Altium and prior to that at KPMG, Roy advised and guided Israeli entrepreneurs and global innovation seekers in several successful cross-border transactions. Roy’s professional expertise lies in both long-range strategic planning and his deep familiarity with the Israeli tech ecosystem. In recent years Roy was fortunate to work closely with brilliant entrepreneurs looking for the right partner to grow their business; with senior executives looking to expand their company’s offerings and with prominent investors searching for the next crop of opportunities in Israel. Roy holds an LLB in Law and a Bachelor’s degree in Accounting from Tel Aviv University.
Partner (UK & EU)
Bamburgh Capital is a boutique Corporate Advisory firm based on the North of England. They offer bespoke advice to businesses and shareholders seeking to raise capital and create then realise value. The team has extensive experience of helping Healthcare businesses across the UK to access a wide range of private and public capital from their national and overseas partners.